Abstract #0149
Early detection of cell death using transmembrane water exchange MRI
Athanasia Kaika1, Luca Nagel1, Bangwen Xie2, Geoffrey J. Topping1, Mathias Schillmaier1, Frits H. A. van Heijster1, Julian Rauch3, Tristan A. Kuder3, Sandra Sühnel1, Simone Ballke4, Katja Steiger4, Philipp Paprottka5, Jonathan Nadjiri5, Kevin M. Brindle2,6, Wolfgang A. Weber1, and Franz Schilling1,7
1TUM School of Medicine and Health, TUM University Hospital, Department of Nuclear Medicine, Technical University of Munich, Munich, Germany, 2Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, United Kingdom, 3Division of Medical Physics in Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany, 4TUM School of Medicine and Health, Institute of Pathology, Munich, Germany, 5TUM School of Medicine and Health, TUM University Hospital, Department of Interventional Radiology, Technical University of Munich, Munich, Germany, 6Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom, 7Munich Institute of Biomedical Engineering, Technical University of Munich, Garching, Germany
Synopsis
Keywords: Novel Contrast Mechanisms, biomarkers, cell death; transmembrane water permeability; water exchange rate
Motivation: Early detection of cell death with FEXI.
Goal(s): Investigate the sensitivity of AXR measurements to tumor cell death after therapy.
Approach: Evaluate FEXI, DWI, hyperpolarized malate/fumarate CSI, H&E histology, and fluorescence imaging in preclinical tumors. Compare FEXI and DWI for clinical uterine fibroids therapy response assessment.
Results:
- AXRs and malate/fumarate ratios correlate, but not with ADC, in solid-growing EL4 lymphoma in mice.
- FEXI and DWI of EL4 lymphoma treated with etoposide or Colo205 colorectal carcinoma treated with a TRAILR2 agonist had increased AXR.
- Clinical FEXI shows sensitivity to embolization after 24 hours.
Impact: Transmembrane water permeability measured by AXR is a sensitive marker for cell death during cancer progression or therapy. FEXI is a contrast agent-free technique that can be easily included in clinical MR protocols.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Click here for more information on becoming a member.
